| Shoreline Foot & Ankle Center, Pc | |
|
85 Poheganut Dr, Groton, CT 06340-3252 | |
| (860) 437-3737 | |
| (860) 437-0530 |
| Full Name | Shoreline Foot & Ankle Center, Pc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 85 Poheganut Dr, Groton, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780733519 | NPI | - | NPPES |
| CH6521 | Other | CT | RAIL ROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shoreline Foot & Ankle Center, Pc 85 Poheganut Dr, Groton, CT 06340-3252 Ph: (860) 437-3737 | Shoreline Foot & Ankle Center, Pc 85 Poheganut Dr, Groton, CT 06340-3252 Ph: (860) 437-3737 |
News Archive
Primary care doctors practicing in a model of coordinated, team-based care that leverages health information technology are more likely to give patients recommended preventive screening and appropriate tests than physicians working in other settings, according to research published today in the Annals of Internal Medicine.
Warning witnesses about the threat of misinformation-;before or after an event-;significantly reduces the negative impact of misinformation on memory, according to new research performed at Tufts University.
It may be difficult for addicted individuals to learn when they can expect a reward. This learning problem could perhaps explain why they are more prone to addiction and find it difficult to kick the habit.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the Southern District of Florida's February 2011 decision that Watson's generic versions of Mucinex(R), Mucinex(R) D, and Mucinex(R) DM Extended-Release products do not infringe U.S. Patent No. 6,372,252.
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).
› Verified 8 days ago
Dr. Darren J Courtright, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 85 Poheganut Dr, Groton, CT 06340 Phone: 860-437-3737 Fax: 860-437-0530 | |
Dr. Sonya Lisa Marshall, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 85 Poheganut Dr, Groton, CT 06340 Phone: 860-437-3737 Fax: 860-437-0530 |